A new botulinum toxin (Xeomin) for cervical dystonia and blepharospasm
- PMID: 21068703
A new botulinum toxin (Xeomin) for cervical dystonia and blepharospasm
Abstract
The FDA has approved incobotulinumtoxinA (Xeomin--Merz) for treatment of cervical dystonia and blepharospasm in adults. It has been commercially available in Germany since 2005. Several formulations of botulinum toxin type A (Botox; Dysport) and type B (Myobloc) are already marketed for treatment of cervical dystonia. Botox is also approved for treatment of blepharospasm.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
